Furio Pacini

List of Publications by Year in descending order

106 papers	30,264 citations	61945 43 h-index	39638 94 g-index
115 all docs	115 docs citations	115 times ranked	15484 citing authors

#	Article	IF	Citations
1	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	2.4	10,674
2	Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2009, 19, 1167-1214.	2.4	6,039
3	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 2006, 154, 787-803.	1.9	1,804
4	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	1.8	1,782
5	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	2.4	1,738
6	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	6.3	1,295
7	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	1.8	574
8	Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 163-168.	1.8	464
9	A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3877-3885.	1.8	447
10	Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology, 2004, 150, 105-112.	1.9	295
11	Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1365-1369.	1.8	295
12	Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes and Endocrinology,the, 2014, 2, 356-358.	5.5	283
13	Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of Endocrinology, 2011, 165, 441-446.	1.9	243
14	Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine, 2006, 47, 648-54.	2.8	209
15	Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1516-1527.	1.8	203
16	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. Lancet Diabetes and Endocrinology,the, 2016, 4, 933-942.	5.5	200
17	131I Therapy for Elevated Thyroglobulin Levels. Thyroid, 1997, 7, 273-276.	2.4	196
18	Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology, 2005, 153, 651-659.	1.9	174

#	Article	IF	Citations
19	Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4063-4068.	1.8	170
20	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5686-5690.	1.8	167
21	A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3542-3546.	1.8	167
22	Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal of Surgery, 1994, 18, 600-604.	0.8	164
23	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodineâ€refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer, 2015, 121, 2749-2756.	2.0	159
24	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	1.6	154
25	Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumour outcome. European Journal of Endocrinology, 1988, 119, 373-380.	1.9	140
26	DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1623-1630.	1.8	109
27	Management of advanced medullary thyroid cancer. Lancet Diabetes and Endocrinology,the, 2016, 4, 64-71.	5.5	100
28	Clinical Features and Therapeutic Implication of Papillary Thyroid Microcarcinoma. Thyroid, 2007, 17, 1085-1092.	2.4	98
29	131I Therapy for Differentiated Thyroid Cancer Leads to an Earlier Onset of Menopause: Results of a Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3512-3515.	1.8	97
30	Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4160-4165.	1.8	90
31	Follicular cell-derived thyroid cancer. Nature Reviews Disease Primers, 2015, 1, 15077.	18.1	88
32	Short Telomeres, Telomerase Reverse Transcriptase Gene Amplification, and Increased Telomerase Activity in the Blood of Familial Papillary Thyroid Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3950-3957.	1.8	80
33	Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. European Journal of Endocrinology, 2013, 169, 23-29.	1.9	80
34	Follow-up of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, S492-S496.	3.3	66
35	Lack of Association between Urinary Iodine Excretion and Successful Thyroid Ablation in Thyroid Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 230-237.	1.8	65
36	Unsuspected Parathyroid Cysts Diagnosed by Measurement of Thyroglobulin and Parathyroid Hormone Concentrations in Fluid Aspirates. Annals of Internal Medicine, 1985, 102, 793.	2.0	63

#	Article	IF	Citations
37	2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. European Thyroid Journal, 2022, 11, .	1.2	62
38	Approach to and Treatment of Differentiated Thyroid Carcinoma. Medical Clinics of North America, 2012, 96, 369-383.	1.1	61
39	Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2693-2700.	1.8	61
40	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5686-5690.	1.8	60
41	Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4190-4198.	1.8	53
42	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology, 2013, 31, 4-4.	0.8	48
43	Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 1009-1021.	2.2	45
44	Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Review of Endocrinology and Metabolism, 2012, 7, 541-554.	1.2	42
45	Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine, 2019, 64, 122-129.	1.1	39
46	Management of thyroid nodules: a clinicopathological, evidence-based approach. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1443-1449.	3.3	38
47	Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study. Thyroid, 2016, 26, 1563-1572.	2.4	36
48	Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome.. Obesity Surgery, 2017, 27, 1750-1754.	1.1	34
49	Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine, 2017, 58, 535-541.	1.1	33
50	Thyroid microcarcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 381-389.	2.2	32
51	Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1327-E1331.	1.8	31
52	Presurgical Serum Thyroglobulin Has No Prognostic Value in Papillary Thyroid Cancer. Thyroid, 2005, 15, 1041-1045.	2.4	29
53	Telomere Length in Neoplastic and Nonneoplastic Tissues of Patients with Familial and Sporadic Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1852-E1856.	1.8	28
54	IFNγ-Inducible Chemokines Decrease upon Selenomethionine Supplementation in Women with Euthyroid Autoimmune Thyroiditis: Comparison between Two Doses of Selenomethionine (80 or 160 Î¼g) versus Placebo. European Thyroid Journal, 2015, 4, 226-233.	1.2	28

#	Article	IF	Citations
55	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. Laboratory Investigation, 2000, 80, 1413-1419.	1.7	26
56	Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer. Thyroid Research, 2010, 3, 4.	0.7	25
57	Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules. European Thyroid Journal, 2016, 5, 125-131.	1.2	25
58	How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 641-650.	2.9	24
59	Weight Loss Associated with Bariatric Surgery Does Not Restore Short Telomere Length of Severe Obese Patients After 1ÂYear. Obesity Surgery, 2014, 24, 2089-2093.	1.1	24
60	Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelinesâ€"â€œThe Italian Wayâ€• Thyroid, 2018, 28, 551-555.	2.4	24
61	Thyroid microcarcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 421-429.	2.2	23
62	Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. Lancet Oncology, The, 2018, 19, 1280-1283.	5.1	23
63	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology, 2013, 31, 4-4.	0.8	23
64	Expanding Indications for Recombinant Human TSH in Thyroid Cancer. Thyroid, 2008, 18, 687-694.	2.4	22
65	Management of Papillary Thyroid Microcarcinoma: Primum Non Nocere!. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1391-1393.	1.8	21
66	Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2362-2368.	1.8	19
67	Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. International Journal of Molecular Sciences, 2017, 18, 775.	1.8	18
68	Telomeres and Thyroid Cancer. Current Genomics, 2009, 10, 526-533.	0.7	16
69	Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients. Thyroid, 2017, 27, 1053-1057.	2.4	16
70	The Low Utility of Pretherapy Scans in Thyroid Cancer Patients. Thyroid, 2009, 19, 815-816.	2.4	15
71	Recombinant Human Thyroid-Stimulating Hormone: Use in Papillary and Follicular Thyroid Cancer. Hormone Research in Paediatrics, 2007, 67, 132-142.	0.8	14
72	Which patient with thyroid cancer deserves systemic therapy and when?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 291-294.	2.2	14

#	Article	IF	Citations
73	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. Journal of Clinical Oncology, 2014, 32, 6060-6060.	0.8	14
74	Targeted therapy in refractory thyroid cancer: current achievements and limitations. Future Oncology, 2011, 7, 657-668.	1.1	13
75	Telomerase and the endocrine system. Nature Reviews Endocrinology, 2011, 7, 420-430.	4.3	12
76	Changing natural history of differentiated thyroid cancer. Endocrine, 2012, 42, 229-230.	1.1	12
77	Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. Journal of Endocrinological Investigation, 2001, 24, 445-447.	1.8	11
78	Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2464-e2470.	1.8	11
79	Breakâ€“apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements. European Journal of Endocrinology, 2015, 172, 571-582.	1.9	8
80	Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma. European Thyroid Journal, 2020, 9, 213-220.	1.2	8
81	Prognostic indicators for papillary thyroid carcinoma. Expert Review of Endocrinology and Metabolism, 2017, 12, 101-108.	1.2	7
82	Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 2016, 17, 1759.	1.8	6
83	Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells. Endocrine, 2020, 67, 117-123.	1.1	6
84	Preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, vii.	2.2	3
85	Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 329-330.	3.3	3
86	How Far Should We Go in the Search and Treatment of Recurrent or Persistent Lymph Node Metastases during Follow-Up of Thyroid Cancer Patients?. European Thyroid Journal, 2013, 2, 145-146.	1.2	3
87	Papillary thyroid microcarcinoma and active surveillance â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2016, 4, 976-977.	5.5	3
88	Radioactive Iodine Activities for Postsurgical Thyroid Ablation: The Lower the Better. European Thyroid Journal, 2012, 1, 213-215.	1.2	2
89	Optimizing molecular testing in thyroid nodule cytology. Nature Reviews Endocrinology, 2012, 8, 390-391.	4.3	2
90	Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer. European Thyroid Journal, 2016, 5, 7-8.	1.2	2

#	Article	IF	Citations
91	Does Microscopic Extrathyroidal Extension Confer a Higher Risk of Recurrence in Patients With Well-Differentiated Thyroid Cancer?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3016-e3017.	1.8	2
92	Thyroid Neoplasia. , 2016, , 1601-1628.e10.		1
93	Preferred strategy for postsurgical thyroid ablation in low-risk thyroid cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 590-591.	5.5	1
94	Response Letter to the Editor from Edmundo Avila-Hipolito: â€œLong-Term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunityâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	1.8	1
95	Diagnosis of medullary thyroid cancer. F1000 Medicine Reports, 2009, 1, .	2.9	1
96	Thyroid Neoplasia. , 2010, , 1668-1701.		1
97	Lâ€™uso del TSH umano ricombinante (rhTSH) nel follow-up del carcinoma tiroideo differenziato. L Endocrinologo, 2003, 4, 198-203.	0.0	0
98	Microcarcinoma papillare della tiroide: il piÃ¹frequente dei tumori endocrini. L Endocrinologo, 2007, 8, 94-101.	0.0	0
99	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2007, 54, 390.e1-390.e16.	0.8	0
100	Follow-up del paziente con carcinoma differenziato della tiroide secondo le linee di consenso internazionali. L Endocrinologo, 2010, 11, 2-6.	0.0	0
101	Innovazioni nel dosaggio della tireoglobulina circolante nei pazienti con carcinoma differenziato della tiroide. L Endocrinologo, 2010, 11, 248-253.	0.0	0
102	Management of differentiated thyroid cancer of the follicular epithelium. Annals of Medicine, 2012, 44, 651-655.	1.5	0
103	Post-surgical thyroid ablation in intermediate risk-differentiated thyroid cancer patients. European Journal of Endocrinology, 2013, 169, L2.	1.9	0
104	Endopoints for screening thyroid cancer in the Republic of Korea: thyroid specialistsâ€™ perspectives. Journal of Endocrinological Investigation, 2017, 40, 689-690.	1.8	0
105	Authorsâ€™ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodulesâ€”Will the Law Answer before Endocrinologists Do?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4770-4770.	1.8	0
106	Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer. Lancet Diabetes and Endocrinology,the, 2022, , .	5.5	0